Financial Data and Key Metrics Changes - Nuellis generated $2,300,000 in revenue for Q4 2024, a 9% decrease year over year due to a decline in U.S. console sales and international sales, partially offset by a 21% increase in consumables utilization [8][15] - Gross margin improved to 58.4% for Q4 2024 compared to 54.4% in the prior year, driven by higher manufacturing volumes of consumables and lower fixed overhead manufacturing expenses [16] - Net loss attributable to common shareholders in Q4 was $1,500,000 or a loss of $0.44 per share, an improvement from a net loss of $7,900,000 or a loss of $54.48 per share in the same period in 2023 [18] Business Line Data and Key Metrics Changes - The critical care customer category posted a 35% year-over-year revenue growth, benefiting from higher console sales and consumable utilization [9][15] - Heart failure and pediatric customer categories experienced declines of 36% and 20% respectively due to lower console sales [9][15] Market Data and Key Metrics Changes - The company reported nine new account wins throughout 2024, indicating positive market penetration [7] - A new reimbursement change effective January 1, 2025, increased the facility reimbursement fee for Aquadex Ultrafiltration therapy nearly fourfold, from $413 to $1,639 per day, allowing entry into the outpatient market [11] Company Strategy and Development Direction - The company aims to build its clinical evidence to make Aquadex Ultrafiltration Therapy a standard of care and integrate it into medical society guidelines [10] - The focus remains on driving market penetration of Aquadex Ultrafiltration Therapy, leveraging clinical evidence and increased reimbursement in the outpatient setting [12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2025, highlighting the positive impact of new reimbursement changes and clinical data supporting Aquadex therapy [7][10] - The management acknowledged the importance of the recent publication in JACC Heart Failure, which demonstrated significant clinical benefits of Aquadex over traditional IV diuretics [10][31] Other Important Information - The company had $5,100,000 in cash and cash equivalents with no debt on the balance sheet as of December 31, 2024 [18] - A voluntary recall of specific lots of blood circuit units incurred a non-recurring expense of approximately $150,000 [16] Q&A Session Summary Question: Initial traction in the outpatient setting for Aquadex - Management noted that traction is beginning with several existing accounts needing to set up permanent outpatient facilities, with more activity expected in the coming month [21] Question: Number of Aquadex units sold in Q4 2024 - Three units were sold in Q4 2024, compared to eleven units in Q3 2024 [23] Question: Timing for completion of the REVERSE HF trial enrollment - Management indicated that it is difficult to gauge the timing for completion of enrollment but is pleased with investigator engagement [24] Question: Search for a new CEO - The search for a new CEO is actively underway, with a search firm hired and potential candidates being considered [33]

Investment Rating - The report does not explicitly state an investment rating for the industry [5] Core Insights - The pharmaceutical and biotechnology sector saw a weekly increase of 1.06%, underperforming compared to the Wind All A index (2.43%) and the CSI 300 index (1.39%). The AI + healthcare sector experienced a significant rebound [10][11] - Key sectors that performed well include in vitro diagnostics (4.45%), active pharmaceutical ingredients (2.08%), and hospitals (1.85%). Conversely, offline pharmacies (-0.59%) and medical devices (-0.08%) saw declines [10][11] - The government work report emphasized strengthening basic medical and health services, implementing a health-first development strategy, and promoting the coordinated development of healthcare, medical insurance, and pharmaceuticals [12][14] - On March 8, Huawei announced the establishment of a healthcare division, aiming to integrate its expertise in 5G, cloud computing, and edge computing to develop AI-assisted diagnostic solutions [12][14] Weekly Market Review - The pharmaceutical and biotechnology sector increased by 1.06%, lagging behind the Wind All A index (2.43%) and the CSI 300 index (1.39%). The AI + healthcare direction showed a notable rebound [10] - The top-performing sub-sectors included in vitro diagnostics (4.45%), active pharmaceutical ingredients (2.08%), and hospitals (1.85%), while offline pharmacies (-0.59%) and medical devices (-0.08%) were the worst performers [10][11] - The top three gaining stocks were Hotgen Biotech (38.63%), Berry Genomics (34.39%), and Anbiping (25.72%), while the top three losing stocks were Jiangsu Wuzhong (-14.34%), ST Sansheng (-9.83%), and Baile Tianheng-U (-9.44%) [12][14] Industry News and Key Company Announcements - The government work report highlighted the need to enhance basic medical services and improve the healthcare system, including reforms in public hospitals and drug procurement policies [12][14] - Huawei's new healthcare division aims to leverage its technological strengths to accelerate the development of medical AI models for clinical applications [12][14] - On March 8, Ausgen announced that the FDA accepted its new drug application for AUKONTALS, a treatment for amyotrophic lateral sclerosis, with a decision expected by October 23, 2025 [12][14] - CloudTop announced the successful administration of its mRNA personalized cancer vaccine EVM16 in a clinical trial, marking a significant milestone in its development [12][14]

Group 1: Trade and Economic Measures - The Chinese government will impose tariffs on certain imported goods from Canada starting March 20, 2025, citing violations of WTO rules and discriminatory practices against China [1] Group 2: Real Estate Market - The Ministry of Housing and Urban-Rural Development aims to stabilize the real estate market by continuing efforts to ensure housing delivery and increasing loan support for projects [2] - Initiatives include urban village renovations, acquisition of existing properties, and reforms to improve the real estate development and sales systems [2] Group 3: Monetary Policy and Reserves - The People's Bank of China has increased its gold reserves for the fourth consecutive month, reaching 7.361 million ounces (approximately 2289.53 tons) by the end of February [3] - Foreign exchange reserves rose to $322.72 billion, an increase of $18.2 billion from the previous month [3] Group 4: Consumer Price Index - In February, the national consumer price index (CPI) decreased by 0.7% year-on-year, with food prices down by 3.3% and non-food prices down by 0.1% [4] - The average CPI for January and February showed a slight decline of 0.1% compared to the same period last year [4] Group 5: Childcare Subsidies - The National Health Commission is drafting an operational plan for childcare subsidies to reduce the costs of childbirth, upbringing, and education [5] - The plan aims to enhance integrated childcare services and provide more inclusive support for families needing childcare [5] Group 6: Healthcare Industry - Huawei has officially established a healthcare division focused on AI-assisted diagnostic solutions, signaling its entry into the AI healthcare sector [6] - The division will leverage various AI models to enhance clinical applications in the medical field [6] Group 7: Stock Market Updates - The Shanghai Stock Exchange announced adjustments to the Hong Kong Stock Connect eligible stocks, effective March 10, 2025, with 27 stocks added and 28 stocks removed from the list [7] - The adjustments reflect changes in the Hang Seng Composite Indexes [7] Group 8: Egg Price Surge - The U.S. Department of Justice is investigating a surge in egg prices, with wholesale prices reaching an all-time high of $8.41 per dozen, a year-on-year increase of over 200% [8] - Major suppliers like Cal-Maine Foods and Rose Acre Farms are under scrutiny for potential price-fixing [8] Group 9: IPO and New Stock Offerings - The China Securities Regulatory Commission approved two IPO registrations, with five new stocks available for subscription from March 10 to March 14 [9] - The new offerings include stocks from various sectors, indicating ongoing market activity [9] Group 10: Stock Unlocking Events - A total of 34 stocks will face unlocking events this week, with a combined market value of approximately 36.158 billion yuan [10] - Notable stocks with significant unlocking ratios include WanKong Intelligent Manufacturing and Jiangxin Home [10]

Financial Data and Key Metrics Changes - Lifeward reported record revenue of $7.5 million in Q4 2024, compared to $6.9 million in Q4 2023, marking an increase of approximately 8.7% [17] - For the full year 2024, revenue reached $25.7 million, an 85% increase from the previous year, representing the highest annual revenue performance in the company's history [17] - GAAP gross margin for Q4 2024 was 24.4%, down from 35.5% in Q4 2023, primarily due to restructuring charges [23] - Non-GAAP adjusted gross margin was 45.4% in Q4 2024, slightly below the 46.9% in Q4 2023 [24] - GAAP operating loss for Q4 2024 was $15.2 million, compared to a loss of $6.7 million in the prior year [26] - Non-GAAP adjusted operating loss improved to $3.3 million in Q4 2024 from $3.8 million in Q4 2023 [27] Business Line Data and Key Metrics Changes - Revenue from traditional products and services, including ReWalk's exoskeletons and Myocycles, was $2.0 million in Q4 2024, while AlterG products generated $5.5 million, the highest quarterly revenue since acquisition [18] - ReWalk sales were below expectations due to delays in Medicare cases, but a growing volume of qualified leads is anticipated to improve predictability in future performance [18][20] - AlterG systems ended Q4 2024 with a backlog of 25 orders, indicating a seasonal decline but an expected 20% revenue growth in Q1 2025 compared to Q1 2024 [22] Market Data and Key Metrics Changes - The company has over 110 qualified candidates for future ReWalk claim submissions in the U.S. and 44 cases in Germany [20] - Active rentals for ReWalk systems consist of 27 cases, with 24 in Germany and 3 in the U.S. [21] - The workers' compensation market represents about 6% of all spinal cord injuries, a segment previously limited for the company but now accessible through the CorLife partnership [52] Company Strategy and Development Direction - Lifeward aims to maintain reasonable growth while reducing quarterly operating losses, targeting a loss at or below $1 million in Q4 2025 [11] - The company is focusing on higher-margin opportunities and operational efficiencies, including a sustainable growth plan to reduce costs [13][29] - Lifeward plans to expand its market access through partnerships, including a new agreement with CorLife for workers' compensation and an expanded distribution agreement with MYOLYN [38][39] Management's Comments on Operating Environment and Future Outlook - Management views 2024 as a year of meaningful achievements, establishing long-term access to technologies and launching a pathway toward profitability [9] - The company anticipates full-year revenue for 2025 in the range of $28 million to $30 million, with adjusted gross margins between 47% to 49% [30] - Management expressed confidence in the sustainable growth plan, which aims to balance top-line growth with spending discipline [91] Other Important Information - The company ended 2024 with $6.7 million in cash and equivalents and no debt, raising an additional $5 million in January 2025 [27][28] - Lifeward received a going concern qualification from auditors, prompting actions to address balance sheet adequacy [28] Q&A Session Summary Question: How does the company see the growth of each component in the 2025 guidance? - Management indicated that the guidance reflects growth across all three major product lines: ReWalk, AlterG, and MyoCycles, with MyoCycles expected to show the biggest percentage growth due to an expanded distribution agreement [47][49] Question: What impact will the CorLife partnership have on the workers' compensation segment? - The CorLife partnership is expected to provide a larger conduit into the workers' compensation market, allowing for efficient processing and quicker payment cycles [51][52] Question: Will the next-generation ReWalk be introduced this year? - Management confirmed that the next-generation ReWalk is expected to be on the market by mid-2025, pending FDA clearance [54] Question: How are recent announcements factored into revenue guidance? - Management stated that recent partnerships have been factored into the revenue guidance conservatively, with expectations for growth in both CorLife and MYOLYN agreements [57][58] Question: What are the common reasons for patient attrition in ReWalk? - Patient attrition was attributed to seasonal factors and deferrals rather than losses, with management noting that these are common in the patient population [66][67] Question: What are the learnings from Medicare reimbursements? - The reimbursement cycle with Medicare has been longer than expected, but management anticipates it will shorten as they gain more experience [72][74] Question: Is the focus on workers' compensation a reaction to federal government policies? - Management clarified that the focus on workers' compensation is driven by opportunity rather than a reaction to government policies [77]

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical industry, indicating that the industry is expected to outperform the benchmark index over the next 12 months [33]. Core Insights - The pharmaceutical sector is experiencing a recovery, with significant growth in sub-sectors such as internet healthcare, biotechnology, and medical devices, which saw increases of 36%, 34%, and 24% respectively in February 2025 [3][6]. - The report highlights the government's encouragement of innovative drug development, including discussions on expanding payment channels for innovative drugs and the potential establishment of a category for innovative drugs in the insurance framework [4][24]. - The medical device market is showing signs of recovery, with the domestic medical imaging equipment market growing over 47% year-on-year in January 2025, and an increase in the number of CT devices awarded contracts by 4.2% compared to the previous year [4][30]. Market Review - In February 2025, the Hang Seng Composite Industry Index rose by 12.8%, while the Hang Seng Healthcare Index increased by 16.3%, outperforming the market by 3.5 percentage points [3][6]. - The A-share market saw the Shanghai and Shenzhen 300 Index decline by 3% in January, with the pharmaceutical and biotechnology index dropping by 3.8%, but rebounding in February with a 5.1% increase [14]. - The report notes that all 13 sub-sectors in the pharmaceutical industry experienced declines in January, but several sub-sectors, including hospitals and medical devices, showed significant gains in February [14]. Industry Data Update - The report indicates that the basic medical insurance revenue for January 2025 reached 314.3 billion yuan, a year-on-year increase of 10.4%, with expenditures growing by 8.5% [17]. - The commercial health insurance sector is also expanding, with original premium income reaching 977.3 billion yuan in 2024, reflecting an 8.2% year-on-year growth [20]. - Medical device exports, particularly for ECG recorders, ultrasound diagnostic devices, and CT machines, have accelerated in both quantity and value since the second half of 2024 [21]. Industry News Summary - The National Healthcare Security Administration held a meeting to support innovative drug development, engaging with major pharmaceutical companies to discuss strategies for enhancing the market for innovative drugs [23][24]. - A draft opinion on improving the drug pricing mechanism has circulated, proposing measures to support innovative drug development and enhance drug accessibility [28]. - The report mentions ongoing efforts to regulate prices in the healthcare sector, including a comprehensive governance initiative for central venous catheter pricing, which has led to significant price reductions for related medical services [29][30].

Investment Rating - The report maintains a "Recommended" rating for the company, indicating a forecasted increase of over 10% relative to the benchmark index in the next 12 months [1][5]. Core Insights - The company has shown a significant quarter-on-quarter recovery in Q4 2024, driven by innovation and expansion into overseas markets. The revenue for Q4 2024 reached 33.46 billion RMB, reflecting a year-on-year decrease of 15.90% but a substantial quarter-on-quarter increase of 106.43% [3][6]. - The company is focusing on increasing R&D investments and optimizing operational efficiency, which is expected to drive a return to growth. New innovative products, such as silicon carbide MRI and zero-noise DSA, are anticipated to create new growth opportunities [6][5]. - The company achieved a total revenue of 103.00 billion RMB in 2024, a year-on-year decline of 9.73%, with a net profit of 12.62 billion RMB, down 36.08% year-on-year. However, projections for 2025 and 2026 indicate a recovery with expected revenues of 124.13 billion RMB and 150.58 billion RMB, respectively [3][5]. Financial Performance Summary - The company’s total revenue for 2024 is projected at 103.00 billion RMB, with a year-on-year growth forecast of 20.51% for 2025 and 21.31% for 2026 [5][10]. - The net profit for 2024 is expected to be 12.62 billion RMB, with a significant recovery projected for the following years, reaching 18.46 billion RMB in 2025 and 23.72 billion RMB in 2026 [5][10]. - The earnings per share (EPS) is forecasted to be 1.53 RMB in 2024, increasing to 2.24 RMB in 2025 and 2.88 RMB in 2026 [10].

Investment Rating - The report does not explicitly provide an investment rating for the industry Core Insights - The A-share market experienced increased trading activity with an average daily turnover of 1.96 trillion yuan, but overall market sentiment was bearish, leading to a decline in major indices [1][14] - The report highlights a shift in market focus towards value stocks and high-dividend sectors due to rising risk aversion amid escalating trade tensions and profit-taking behavior [2][15] - The manufacturing PMI improved from 49.1% to 50.2%, indicating a recovery in economic activity, while the service sector showed signs of decline post-Spring Festival [3][10] - The report notes a cyclical recovery in various industries, including steel, chemicals, and automotive, with property sales also showing a seasonal uptick [4][14] Summary by Sections Macro Economy and Policy Dynamics - The manufacturing PMI rose to 50.2%, reflecting stronger recovery compared to the previous year, driven by robust resumption of work and strong export demand [3][10] - The U.S. PCE inflation showed a slight decrease, with personal income rising by 0.9% while personal spending declined by 0.2%, indicating cautious consumer behavior [3][12] Industry Monitoring - The report indicates a cyclical recovery in the steel, chemical, and automotive sectors, with property sales showing a seasonal increase [4][14] - The average wholesale price of pork increased to 21.21 yuan/kg, while vegetable prices fell to 4.89 yuan/kg, reflecting mixed trends in commodity prices [4][16] Funding Trends - The report notes a net injection of 137 billion yuan in the open market, with a decrease in IPO and private placement fundraising compared to the previous month [5][18] - The total turnover rate for A-shares was recorded at 1.26%, indicating a slight increase in trading activity [5][18] Industry Performance - Among the 30 sectors, steel, construction materials, and real estate showed positive returns, while sectors like telecommunications and media faced significant declines [16][19] - The report emphasizes the importance of monitoring the technology, manufacturing, consumption, and pharmaceutical sectors for long-term investment opportunities [2][15] Consumer Trends - The report discusses the evolving consumer preferences towards snacks over traditional meals, highlighting a shift in purchasing behavior due to inflation [26][27] - The white liquor industry is experiencing supply adjustments to stabilize prices, with major brands implementing supply controls [25][27] Future Outlook - The report suggests that the upcoming Two Sessions may provide clarity on economic policies and growth targets, which could influence market sentiment [31][33] - The report anticipates a continued focus on AI and cloud computing investments, particularly from major players like Alibaba, indicating growth potential in these sectors [29][30]

Financial Data and Key Metrics Changes - Revenue for Q4 2024 totaled $6.3 million, a 39% year-over-year increase compared to $4.6 million in Q4 2023 [37] - Full year revenue for 2024 was $26.9 million compared to $26.8 million in 2023 [38] - Operating loss for Q4 2024 was $7.6 million, compared to $5.3 million in Q4 2023 [41] - Adjusted operating loss for the full year 2024 was $12.8 million, compared to $11.3 million in the prior year [42] Business Line Data and Key Metrics Changes - System revenue for Q4 2024 was $1.4 million, compared to $0.1 million in Q4 2023 [37] - Recurring revenue for Q4 2024 was $4.9 million, reflecting a full quarter's contribution from the acquisition of APT, compared to $4.5 million in Q4 2023 [37] - Full year system revenue was $8.6 million, compared to $8.7 million in the prior year [38] Market Data and Key Metrics Changes - The company expects to achieve approximately $1 million of MAGIC revenue per quarter in Europe by the end of 2024 [20] - The company anticipates a few GenesisX system sales this year, scaling to double-digit numbers next year [18] Company Strategy and Development Direction - The company aims to improve endovascular surgery with robotics, focusing on four primary pillars: making the robot widely available, building an ecosystem of catheters, developing interventional devices, and establishing connectivity and AI capabilities [11][12] - A strategic acquisition of APT has enhanced the company's catheter development and manufacturing capabilities [13] - The company is focused on expanding its addressable market by introducing a family of interventional guidewires and catheters [28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the regulatory milestones and early commercial efforts setting the stage for substantial growth in 2026 [35] - The company expects to keep adjusted operating expenses flat over the next few quarters while investing in commercial capabilities funded by profits from new product launches [47] - Management noted that the existing balance sheet allows the company to reach key milestones and profitably grow [48] Other Important Information - The company has a system backlog of $15.2 million as it enters 2025 [38] - The gross margin for recurring revenue was 70%, while system gross margin was 20% [39] Q&A Session Summary Question: Can you provide more color around MAGIC in the US market? - Management indicated that patient enrollment in Europe is ongoing and that the FDA is conducting a detailed review of the PMA submission, with no definitive number of patients needed for approval [50][52] Question: How will MAGIC Sweep fit into the broader ecosystem? - Management explained that MAGIC Sweep is a high-density mapping catheter that will enhance robotic procedures by providing safety and precision, which has been a long-standing request from physicians [57][62] Question: Can you clarify the system revenue guidance for 2025? - Management stated that the guidance reflects a conservative approach due to the volatility in revenue recognition and ongoing construction timelines for system sales [68][70] Question: What is the expected timing for GenesisX commercial approval in the US? - Management expects to respond to FDA questions soon and anticipates approval before compatible catheters are available [75][76] Question: What is the revenue expectation for the EMAGIN vascular guidance catheter? - Management noted that there are no significant revenue expectations for EMAGIN in the guidance due to uncertainty around regulatory approval [80]

Financial Data and Key Metrics Changes - Revenue for Q4 2024 was $18.5 million, reflecting a 41% growth compared to $13.1 million in Q4 2023 [31] - Full-year revenue totaled $65.4 million, representing a 45% growth over 2023 [33] - Gross margin for Q4 2024 was 88%, up from 85% in the prior year, while full-year gross margin was 87%, compared to 84% in 2023 [34][35] - Net loss for Q4 2024 was $12.6 million, or a loss of $0.40 per share, compared to a loss of $8.3 million, or a loss of $1.53 per share in Q4 2023 [36] Business Line Data and Key Metrics Changes - Product revenue for Q4 2024 was $14.1 million, a 41% increase from $10.0 million in Q4 2023 [32] - Subscription revenue for Q4 2024 was $4.4 million, representing a 40% increase from $3.1 million in Q4 2023 [32] - Active accounts increased to 529 as of December 31, 2024, an increase of 25 accounts during the quarter [16] Market Data and Key Metrics Changes - The company estimates there are 6,000 acute care facilities in the U.S. that could benefit from its offerings, with plans to target approximately 5,500 remaining prospective accounts [17] - The company is focused on expanding its market presence within the current $2 billion market in the U.S. for seizure detection and management in acute care settings [29] Company Strategy and Development Direction - The company aims to maintain its focus on commercial growth and expand its R&D pipeline, with a goal of becoming the standard of care for seizure management in acute care settings [22] - Plans for 2025 include expanding the account acquisition team to 55 territory managers and increasing awareness of the clinical and economic benefits of rapid EEG monitoring [21] - The company envisions expanding its product indications beyond seizure detection, including developing algorithms for delirium and stroke detection [25][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving cash flow breakeven and highlighted the strength of the balance sheet following a successful IPO [41] - The company anticipates total revenue for 2025 to be in the range of $81 million to $85 million, representing annual growth of 24% to 30% over 2024 [37] - Management noted that while accelerated initiatives may not drive immediate revenue, they are expected to have long-term impacts [40] Other Important Information - The company has received breakthrough device designation from the FDA for its delirium detection algorithm, with plans to submit an application later this year [25] - The transition to operating as a public company has increased stock-based compensation costs, expected to contribute approximately $15 million to operating expenses for the full year 2025 [41] Q&A Session Summary Question: Can you elaborate on the guidance for this year and the underlying assumptions? - Management indicated that guidance reflects continued investment in sales infrastructure, which is expected to accelerate growth in 2026 and beyond [46] Question: What are your thoughts on gross margin and OpEx spend in 2025? - Management noted that gross margins are expected to normalize in the mid to high 80% range due to increased tariffs and that R&D expenses are expected to increase by 40% to 60% year-over-year [54][56] Question: Can you provide updates on the stroke opportunity and the algorithm development? - Management expressed satisfaction with the progress in the stroke trial and plans to expand enrollment speed to gather more data for algorithm training [70] Question: How do you see utilization picking up with the new indications? - Management explained that the new indications will work synergistically to help doctors differentiate between various neurological conditions, enhancing overall patient care [83]

Investment Rating - Industry investment rating: Outperform the market (expected to outperform the CSI 300 index by more than 5% in the next 6 months) [1][44] Core Viewpoints - The overall procurement scale in 2024 is expected to be 137.1 billion yuan, a year-on-year decrease of 20%, primarily due to the pace of equipment updates at the beginning of 2024. However, a significant improvement is anticipated in Q4 2024 and Q1 2025 due to rapid implementation of equipment updates and accelerated budget usage by hospitals [3][11] - High-end imaging equipment is experiencing a notable recovery in bidding activities, with significant year-on-year growth rates observed in CT and MRI equipment procurement in late 2024 and early 2025 [5][19] - The domestic equipment localization rate is steadily increasing, driven by intensified price competition and supportive policies for domestic medical devices. Leading domestic companies are gaining market share in key equipment categories [6][31] Summary by Sections Procurement Scale and Trends - The procurement scale for medical devices in 2024 is projected to be 137.1 billion yuan, down 20% year-on-year, with a recovery expected in Q4 2024 due to equipment updates and budget utilization [3][11] - In December 2024, procurement reached 25.3 billion yuan, a 49% increase year-on-year, and in January 2025, it reached 16.9 billion yuan, a 40% increase year-on-year [3][11] High-end Imaging Equipment - High-end imaging equipment, particularly CT and MRI, is seeing a resurgence in procurement, with December 2024 CT procurement growing by 70% year-on-year and MRI by 55% [5][19] - PET equipment also shows significant growth, with December 2024 procurement increasing by 200% year-on-year and January 2025 by 546% [5][19] Localization Rate - The localization rate for major medical equipment is expected to improve in 2024, supported by competitive pricing and government policies favoring domestic products [6][30] - Leading domestic companies such as Mindray, United Imaging, and others are expected to increase their market share in key segments like CT, MRI, and PET equipment [31][30] Investment Recommendations - Looking ahead to 2025, the ongoing equipment update policies are expected to positively impact industry bidding growth. Key companies in high-end and intelligent medical equipment should be closely monitored [40][41]